Q-omics provides the consensus-scored SHISA7 profile across patient tissues and cancer cell-line models. SHISA7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHISA7 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, SHISA7 RNA expression shows 15,941 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where SHISA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISA7 survival associations across molecular data types. SHISA7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISA7 RNA expression–survival associations across cancer types. High SHISA7 expression shows unfavorable associations in KIRC, THCA, BLCA, KICH and KIRP, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHISA7 RNA expression.
This table summarizes SHISA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SHISA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISA7 shows lower tumor expression in COAD and BLCA and higher tumor expression in HNSC, LUSC, KIRP and KIRC. The HNSC box plot shows higher SHISA7 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p < 0.001).
This table shows molecular features associated with SHISA7 in patient tissues and cancer cell lines. In patient samples, SHISA7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SHISA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
